ClinicalTrials.gg

Program

quemliclustat

Also written as “Quemliclustat” and “AB680”.

Its studies are mostly in Pancreatic Neoplasms · Adenocarcinoma Of Esophagus · Carcinoma, Non-Small-Cell Lung, led by 2 companies.

Furthest: phase 3, since Sep 20, 20247 company-led studies, 2 open or runningNext primary completion: Dec 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Arcus Biosciences61 open or runningphase 3since Sep 20, 2024Sep 18, 2018Nov 30, 2030phase 3 · NCT06608927
Gilead Sciences11 open or runningphase 2since Dec 9, 2022Dec 9, 2022Dec 2027phase 2 · NCT05676931

Also a collaborator on its studies: Otsuka.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 18, 2018First study: phase 1 study in Healthy VolunteersNew to Arcus BiosciencesArcus Biosciences · NCT03677973 · 64 enrolled · Australia
  2. Sep 23, 2019Phase 1 study in Pancreatic NeoplasmsArcus Biosciences · NCT04104672 · 196 enrolled · United States
  3. Sep 29, 2020Phase 1 study in Healthy VolunteersArcus Biosciences · NCT04575311 · 32 enrolled · Australia
  4. Apr 8, 2022Phase 2 study in Adenocarcinoma Of EsophagusArcus Biosciences · NCT05329766 · 332 enrolled · United States, Canada, Chile and more
  5. Dec 9, 2022Gilead Sciences's first study: phase 2 study in Advanced Non-Small Cell Lung CancerNew to Gilead SciencesGilead Sciences · NCT05676931 · 400 enrolled · United States, Australia, France and more
  6. Sep 20, 2024Phase 3 study in Pancreatic NeoplasmsArcus Biosciences · NCT06608927 · 610 enrolled · United States, Australia, Austria and more
  7. Jan 16, 2026Phase 1 study in Healthy ParticipantsArcus Biosciences · NCT07364214 · 8 enrolled · United States

Ahead

  1. Dec 2027Primary completion: phase 2 study in Advanced Non-Small Cell Lung CancerGilead Sciences · NCT05676931
  2. Nov 30, 2030Primary completion: phase 3 study in Pancreatic NeoplasmsArcus Biosciences · NCT06608927

TargetBeta

NT5E →read by rule
“A small molecule, competitive inhibitor of the ectoenzyme CD73 (cluster of differentiation 73; 5'-ecto-nucleotidase; 5'-NT; ecto-5'-nucleotidase), ”NCIt, by rule

Other programs on NT5E

ProgramCompanyFurthest phaseStudies
oleclumabAstraZenecaphase 38
uliledlimabruletj-biopharma-co-ltdphase 34

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07364214Healthy Participants · United States1CompletedArcus BiosciencesApr 6, 20268
NCT06608927Pancreatic Neoplasms · United States, Australia, Austria and more3Active, not recruitingArcus BiosciencesNov 30, 2030610
NCT05676931Advanced Non-Small Cell Lung Cancer · United States, Australia, France and more2Active, not recruitingGilead SciencesDec 2027400
NCT05329766Adenocarcinoma Of Esophagus · United States, Canada, Chile and more2CompletedArcus BiosciencesSep 7, 2026332
NCT04575311Healthy Volunteers · Australia1CompletedArcus BiosciencesSep 22, 202132
NCT04104672Pancreatic Neoplasms · United States1CompletedArcus BiosciencesJul 21, 2026196
NCT03677973Healthy Volunteers · Australia1CompletedArcus BiosciencesAug 19, 201964

How it is read

Names in the registry

  • “Quemliclustat”, 4 entries
  • “AB680”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.